Dupixent Lawsuit

March 31st, 2026: ​​Alleged Cancer Risk Withheld from Patients and Medical Community

A Pennsylvania man filed a product liability lawsuit against Dupixent manufacturers Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC on March 25, 2026, in the U.S. District Court for the Eastern District of Pennsylvania.

William Hinton Jr. and his wife, Labarbara, allege the companies failed to warn about the risk of T-cell lymphoma associated with Dupixent (dupilumab), despite knowing of the risks as early as 2018.

Hinton’s complaint states he received Dupixent injections from April 2025 to October 2025 for severe asthma and COPD.

While on the drug, a preexisting rash worsened and new rashes developed. Hinton received a CTCL diagnosis in October 2025 despite no prior history of lymphoma

March 30, 2026: Dupixent Cancer Lawsuits Move Toward Federal MDL Consolidation

Drug manufacturers Sanofi and Regeneron have agreed that lawsuits alleging a link between Dupixent and cancer should be centralized in a federal multidistrict litigation, marking a significant development in the growing number of claims involving the medication.

The litigation centers on allegations that Dupixent may be associated with cutaneous T cell lymphoma, a rare form of non Hodgkin lymphoma.

Plaintiffs claim the drug either caused the cancer, worsened undiagnosed cases, or delayed diagnosis by masking symptoms commonly associated with eczema and other skin conditions.

A motion filed in February 2026 seeks to consolidate the cases under MDL No 3180. At least fifteen lawsuits have already been identified as part of the proposed litigation.

The United States Judicial Panel on Multidistrict Litigation is expected to determine whether the cases will be centralized and where the proceedings will take place.

The Northern District of Georgia has been proposed as a potential venue, though final decisions are pending.

Both plaintiffs and defendants support consolidation, citing overlapping factual questions and the need for coordinated pretrial proceedings.

If established, the MDL would allow one federal judge to oversee discovery and early motions while preserving each plaintiff’s individual claim.

The cases remain in the early stages, and no court has determined whether Dupixent causes or contributes to cancer.

No settlements or trial outcomes have been reached.

March 19, 2026: Florida Woman Files Dupixent Lawsuit After CTCL Diagnosis

A woman in Florida has filed a lawsuit claiming that Dupixent caused her to develop cutaneous T-cell lymphoma (CTCL) after she started treatment for atopic dermatitis.

Sandra Jaeger filed a complaint on March 4 in the U.S. District Court for the Middle District of Florida, naming Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC as defendants.

The lawsuit alleges that the manufacturers did not adequately warn patients and doctors about the potential risk of T-cell lymphoma associated with Dupixent.

Jaeger states she started receiving Dupixent injections in February 2022 for intrinsic atopic dermatitis, with treatments given every two weeks until July 2022.

According to the complaint, she developed enlarged lymph nodes and increased white blood cell counts within a month of starting the medication, which led to her hospitalization in March 2022.

Subsequent testing and a biopsy in April 2022 confirmed lymphoma, leading to a formal diagnosis of cutaneous T-cell lymphoma in June 2022.

The lawsuit states that Jaeger stopped using Dupixent in July 2022 after another hospitalization involving pain and discoloration in her palms and feet.

She later underwent additional testing in February 2025, which led to a diagnosis of anaplastic large cell lymphoma.

Jaeger files claims for failure to warn, negligence, negligent misrepresentation, and breach of warranty, alleging that the manufacturers knew or should have known of the risk of lymphoma but failed to provide adequate warnings.

The case joins a growing number of Dupixent lawsuits alleging a link between the drug and T-cell lymphoma, as plaintiffs aim to consolidate federal claims into a multidistrict litigation.

March 9th, 2026: Dupixent Lawsuit Filed Alleging Failure to Warn About Risk of Cutaneous T-Cell Lymphoma

A newly filed product liability lawsuit alleges that the eczema medication Dupixent caused a woman to develop a rare form of cancer known as mycosis fungoides, a type of cutaneous T-cell lymphoma.

Donareen Oakley and her husband filed a Dupixent lawsuit on March 3 in the U.S. District Court for the Northern District of Georgia. The lawsuit names Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC as defendants.

Plaintiffs claim the manufacturers failed to warn patients and physicians about a potential association between Dupixent and T-cell lymphoma.

Dupixent, also known by the generic name dupilumab, received approval from the U.S. Food and Drug Administration in 2017 for the treatment of atopic dermatitis, a form of eczema.

Drug manufacturers later expanded the label to include treatment for asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory respiratory and skin conditions. Expanded approvals contributed to the widespread use of the medication in the United States.

The Dupixent lawsuit states that Oakley received Dupixent injections from July 2019 through June 2020 after physicians diagnosed her with atopic dermatitis.

The complaint alleges that neither Oakley nor her prescribing physician received warnings about possible risks of cutaneous T-cell lymphoma or the importance of monitoring for symptoms associated with the disease.

Mycosis fungoides represents the most common form of cutaneous T-cell lymphoma (CTCL), a cancer affecting white blood cells that play a central role in the immune system.

March 4th, 2026: Nevada Case Alleges Eczema Drug Caused T-Cell Lymphoma

A newly filed lawsuit claims that the eczema drug Dupixent may have contributed to the development of a rare and aggressive cancer, raising new questions about the medication’s long-term safety profile.

The complaint was filed in the U.S. District Court for the District of Nevada by David Luchsinger and his wife, Cheryl, against Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC.

The lawsuit alleges that the drug manufacturers failed to warn patients and physicians that Dupixent (dupilumab) may increase the risk of T-cell lymphoma, a rare cancer affecting white blood cells that play a critical role in the immune system.

Dupixent was first approved in 2017 to treat atopic dermatitis, commonly known as eczema. It has since been prescribed for a number of inflammatory conditions, including asthma and chronic respiratory diseases, and has reportedly been used by more than one million patients worldwide.

However, emerging research has raised concerns that the drug may trigger or accelerate certain lymphomas, particularly cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).

According to the lawsuit, Luchsinger began receiving Dupixent injections in October 2024 to treat eczema and continued treatment through March 2025.

Prior to starting the medication, he had no history of lymphoma or other related cancers.

Within months of beginning treatment, however, his eczema reportedly worsened rather than improved.

Approximately one year after starting the injections, Luchsinger was diagnosed with mycosis fungoides, a form of cutaneous T-cell lymphoma.

The lawsuit alleges that Dupixent not only contributed to the development of the cancer but also allowed the disease to progress rapidly before it was identified at a late stage.

The complaint claims that the manufacturers failed to adequately test the medication before bringing it to market and ignored growing scientific evidence suggesting a potential connection between Dupixent and T-cell lymphomas.

The lawsuit also alleges that the companies did not warn physicians that patients receiving Dupixent should be monitored for signs of lymphoma development.

The case joins a growing number of Dupixent cancer lawsuits being pursued nationwide.

Plaintiffs in these cases generally argue that drug makers knew or should have known about the potential risk of lymphoma but failed to provide sufficient warnings to the medical community and the public.

Luchsinger and his wife are seeking compensatory and punitive damages, bringing claims for failure to warn, negligence, and loss of consortium as the litigation over Dupixent’s potential cancer risks continues to develop.

March 2, 2026: Dupixent Lawsuits Raise Concerns Over Masked Lymphoma Symptoms

Recent lawsuits involving Dupixent, a drug prescribed for atopic dermatitis and other skin conditions, allege that the medication may conceal signs of cutaneous T‑cell lymphoma (CTCL), a rare form of cancer.

Patients and their families claim that Dupixent’s effectiveness in reducing visible eczema symptoms can delay diagnosis of CTCL, potentially worsening outcomes.

Legal filings focus on whether the manufacturers, Sanofi and Regeneron, provided adequate warnings about this risk.

Attorneys highlight the so-called “masking effect,” where skin improvements may obscure underlying disease, leading to delayed biopsies and treatment.

These claims are being pursued through individual lawsuits in state and federal courts, with some attorneys seeking coordination of cases to streamline litigation.

No settlements or judgments have been reported, and the litigation is ongoing as courts continue to review allegations and potential discovery.

February 26th, 2026: FDA Updates Dupixent Labeling for Allergic Fungal Rhinosinusitis in Adults and Children

Health officials have updated prescribing information for Dupixent (dupilumab) to include treatment of allergic fungal rhinosinusitis (AFRS) in adults and children age 6 and older.

AFRS is a chronic inflammatory sinus condition triggered by an allergic response to fungal organisms, often causing nasal congestion, sinus pressure, polyps, and recurring infections.

Clinical data supporting the update indicate Dupixent can reduce inflammation, decrease polyp size, and lessen the need for systemic steroids or surgery in appropriate patients.

The medication’s safety profile remains consistent with prior labeling, with commonly reported side effects including injection site reactions and eye-related inflammation.

However, Dupixent is also the subject of ongoing litigation involving allegations of serious adverse effects in certain patients.

Lawsuits have raised claims that the manufacturer failed to adequately warn about potential risks and complications associated with the drug.

While the labeling update reflects regulatory recognition of Dupixent’s benefits for AFRS, the broader safety profile of the drug continues to be scrutinized in court.

Lawsuits center on whether risks were sufficiently disclosed and whether patients experienced injuries beyond what was represented in prescribing information.

February 20th, 2026: Dupixent Lymphoma Lawsuits Seek MDL Consolidation

Multiple federal lawsuits have been filed alleging that the drug Dupixent, used to treat eczema and other inflammatory conditions, caused patients to develop T‑cell lymphomas, including cutaneous T‑cell lymphoma.

Dupixent lawsuits claim that the manufacturers, Sanofi and Regeneron, failed to adequately warn doctors and patients about the potential cancer risks.

Plaintiffs have asked the U.S. Judicial Panel on Multidistrict Litigation to consolidate at least 15 cases into a single MDL in the Northern District of Georgia. 

Consolidation into multidistrict litigation (MDL) would centralize pretrial proceedings, reduce duplicate discovery, and address common legal and scientific questions, while each case would remain separate for individual claims.

The motion for MDL was filed in early 2026, and a decision by the panel is pending.

If approved, coordinated discovery and potential bellwether trials would move forward, shaping the resolution of these claims.

February 11th, 2026: New Dupixent Lawsuit Alleges Cancer Risk and Failure to Warn

A Dupixent lawsuit filed in federal court alleges that the eczema drug caused a rare form of lymphoma and that the manufacturers failed to provide adequate safety warnings.

According to the complaint, more than 200 reports have linked Dupixent to cutaneous T-cell lymphoma (CTCL) since the medication received approval in 2017.

A report from the filed complaint states that plaintiff Michael Durkin filed the case on February 4, 2026, in the U.S. District Court for the Middle District of Florida.

The Dupixent lawsuit names Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals Inc. as defendants.

The complaint alleges that the companies knew or should have known that Dupixent side effects included an increased risk of T-cell lymphomas, including CTCL and peripheral T-cell lymphoma (PTCL), and failed to warn patients and prescribing physicians.

The lawsuit states that more than one million patients have used Dupixent during the marketing period.

The complaint alleges that internal safety signals emerged within approximately one year of approval, including more than a dozen early reports of CTCL, which later increased to more than 200 reports by the end of 2024.

February 3rd, 2026: Federal Courts Set Early Response Deadlines as CTCL Claims Take Shape

New federal lawsuits alleging that Dupixent may have caused or accelerated rare cancers like cutaneous T-cell lymphoma (CTCL) are prompting early activity in the courts, including concrete deadlines for defendants to respond.

In one of the first wrongful death cases filed in federal court, a Georgia plaintiff asserts that after being prescribed Dupixent for eczema she later developed CTCL, a rare form of non-Hodgkin lymphoma that primarily affects the skin.

The complaint alleges manufacturers Sanofi and Regeneron Pharmaceuticals failed to warn patients and doctors about this potential risk, arguably delaying proper diagnosis and treatment.

In response, judges in these early actions have moved quickly to set formal deadlines for Sanofi and Regeneron to file their initial court papers.

Those response dates require defendants to answer the complaints or challenge them with motions to dismiss by a specific date, often just weeks after service.

These deadlines signal that judges recognize the complexity of the underlying science, claims about immune-modulating drugs and cancer risk require early clarity about what facts and legal theories will be at issue.

Setting response deadlines early in the case accomplishes several things:

• It starts the clock on key procedural disputes, including motions to dismiss based on preemption, causation, and statute of limitations issues.
• It forces defendants to articulate their defense strategy sooner, rather than delaying while discovery develops.
• It helps frame the litigation schedule, including when expert reports, discovery, and later hearings might occur.

Once defendants file responses, next litigation steps generally include motions to dismiss (where manufacturers may argue plaintiffs have not stated a viable claim), early discovery disputes over medical and regulatory records, and potential coordination of multiple Dupixent cases as filings increase.

January 27th, 2026: Lawyers Urge Dupixent Users to Watch for New Skin Lesions Amid Emerging Litigation Risks

A growing body of concerns is prompting legal and medical professionals to advise patients taking Dupixent, an injectable biologic used for eczema, asthma, and related conditions, to monitor new or unusual skin lesions closely, as some reports suggest a possible association with serious skin abnormalities.

The guidance comes amid an uptick in complaints and inquiries from patients who developed persistent or concerning skin changes after initiating Dupixent, raising potential product liability and failure-to-warn issues.

While manufacturers and regulators state that clinically significant skin tumors are rare and that causation has not been established, plaintiffs’ lawyers emphasize the importance of vigilance.

They note that biologic therapies like Dupixent modulate the immune system in ways that can, in some individuals, alter skin surveillance mechanisms and potentially unmask or accelerate underlying conditions.

In the litigation context, claims may focus on whether patients and clinicians were adequately informed about plausible risks, particularly when new skin lesions arise.

Attorneys monitoring these developments are assessing whether label warnings, post-market surveillance, and risk disclosures reflect the evolving understanding of adverse events.